53
5
2
カタログ番号 | 製品名 | 別名 | ターゲット |
---|---|---|---|
T3711 | RAF709 | Raf | |
RAF709 is a novel Raf kinase inhibitor with IC50s of 0.5 and 1.8 nM for c-Raf and b-Raf, respectively. | |||
T10599 | BRAF inhibitor | Raf | |
BRAF inhibitor is an inhibitor of B-Raf. | |||
T1845 | B-Raf IN 1 | Raf | |
B-Raf IN 1 is a B-Raf (IC50: 24 nM) and c-Raf (IC50: 25 nM) inhibitor. | |||
T2074 | Raf inhibitor 1 | B-Raf inhibitor 1 | Raf |
B-Raf inhibitor 1 (B-Raf inhibitor 1) is a potent and selective B-Raf inhibitor. | |||
T4167 | Raf inhibitor 1 dihydrochloride | B-Raf inhibitor 1 dihydrochloride | Raf |
Raf inhibitor 1 dihydrochloride (B-Raf inhibitor 1 dihydrochloride) is a potent and selective B-Raf inhibitor. | |||
T2295 | SB-590885 | Raf | |
SB590885 is an effective B-Raf inhibitor (Ki: 0.16 nM, in a cell-free assay). The selectivity of SB590885 for B-Raf is 11-fold greater over c-Raf, no acts to other human kinases. | |||
TQ0048 | BI-882370 | Raf | |
BI-882370 is a specific RAF kinase inhibitor. BI-882370 inhibits the oncogenic BRAFV600E-mutant, the WT BRAF and CRAF kinases (IC50s: 0.4, 0.8 and 0.6 nM). BI-882370 also inhibits SRC family kinases. | |||
T15794 | LUT014 | Raf | |
LUT014 is a B-Raf inhibitor (IC50: 11.7 nM) and developed to decrease dose-limiting acneiform lesions associated with EGFR Inhibitors treatment. | |||
T4133 | CCT196969 | Raf , Src | |
CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. It also inhibits SRC, LCK, and the p38 MAPKs. | |||
T4194 | Raf inhibitor 2 | CID-25014542,CID 25014542,CID25014542 | Raf |
Raf inhibitor 2 (CID 25014542) is novel inhibitor of Raf kinases. | |||
T2473 | PLX-4720 | PLX4720 | Raf |
PLX-4720 is a potent and selective inhibitor of B-Raf (V600E) (IC50: 13 nM), equally potent to c-Raf-1(Y340D and Y341D mutations). | |||
T5172 | AZ304 | c-Fms , Raf , p38 MAPK , Autophagy | |
AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits BRAF (WT), BRAF (V600E), and wild type CRAF (IC50s: 79/38/68 nM). | |||
T6318 | AZ 628 | Apoptosis , Raf | |
AZ628 is a new pan-Raf inhibitor for BRAF, BRAFV600E, and c-Raf-1 with IC50 of 105 nM, 34 nM and 29 nM, also inhibits VEGFR2, DDR2, Lyn, Flt1, FMS, etc. | |||
T6296 | RAF265 | CHIR-265 | Apoptosis , Raf , VEGFR , Autophagy |
RAF265 (CHIR-265) (CHIR-265) is a potent selective inhibitor of C-Raf/B-Raf/B-Raf V600E with IC50 of 3-60 nM, and exhibits potent inhibition on VEGFR2 phosphorylation with EC50 of 30 nM. Phase 2. | |||
T1886 | TAK-632 | Raf , FGFR , PDGFR , Aurora Kinase | |
TAK-632 is a potent pan-Raf inhibitor. | |||
T6487 | Encorafenib | LGX818 | Raf |
Encorafenib (LGX818) is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity. | |||
T1953 | L-779450 | L 779450 | Raf , Autophagy |
L-779450, an effective, ATP-competitive Raf kinase inhibitor (IC50: 10 nM) , displays > 7, > 30 and > 70-fold selectivity over p38α, GSK3β and Lck respectively. | |||
T11224 | Rineterkib | ERK-IN-1 | ERK , Raf |
T24437 | MCP110 | MCP-110,MCP 110 | Raf , Ras |
MCP110 is an inhibitor of the interaction of Ras with Raf-1 and can be used in studies about the treatment of human tumors. | |||
T1851 | ZM 336372 | Zinc00581684 | Apoptosis , Raf |
ZM 336372 is a potent and selective c-Raf inhibitor. | |||
T9693 | TBAP-001 | Raf | |
TBAP-001 is a RAF kinase inhibitor, with an IC50 of 62 nM in BRAF V600E kinase assay and an IC50 of 18 nM in Cell-Based Phosho-ERK Assay. | |||
T4301 | AD80 | Raf , c-RET , Src , S6 Kinase | |
AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity. | |||
T5634 | Belvarafenib | Raf | |
Belvarafenib is a potent and pan RAF inhibitor with antineoplastic activity. The IC50 values of Belvarafenib are 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively. | |||
T1903 | Dabrafenib | GSK2118436A,GSK2118436 | Raf |
Dabrafenib (GSK2118436A) is a Raf inhibitor that inhibits C-Raf and B-RafV600E (IC50=5/0.6 nM) and is ATP-competitive. Dabrafenib exhibits antitumor activity for the treatment of B-RafV600E-mutated melanoma. | |||
T6949 | PLX7904 | PB04 | Raf |
PLX7904 (PB04), also known as PB04, is a potent and selective paradox-breaker RAF inhibitor. It is able to efficiently inhibit activation of ERK1/2 in mutant BRAF melanoma cells but does not hyperactivate ERK1/2 in mutan... | |||
T6320 | GDC-0879 | GDC 0879,AR-00341677,GDC0879 | Raf |
GDC-0879 (AR-00341677) is a novel, potent and selective B-Raf inhibitor with IC50 of 0.13 nM with activity against c-Raf as well. | |||
T11898 | LXH254 | Raf | |
LXH254 is a potent C-Raf and B-Raf inhibitor. | |||
T6882 | LY3009120 | DP-4978 | Raf , Autophagy |
LY3009120 (DP-4978) is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1. | |||
T41003 | KG5 | Raf , FLT , PDGFR , c-Kit | |
KG5 is a dual allosteric inhibitor of PDGFRβ and B-Raf with a Kd of 520 nM and 300 nM for PDGFRβ and PDGFRα. KG5 inhibits FLT3, KIT, and c-Raf with anticancer and antiangiogenic activities. | |||
T6277 | Doramapimod | BIRB 796 | Raf , p38 MAPK , Autophagy |
Doramapimod (BIRB 796) is a highly potent inhibitor of p38 MAPK (Kd: 0.1 nM), but weakly inhibits c-RAF, Fyn, Lck, ERK-1, SYK, IKK2, and ZAP-70. | |||
T22272 | Lifirafenib | BGB-283,Beigene-283 | EGFR , Raf |
Lifirafenib (Beigene-283) is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant respective... | |||
T8745 | PROTAC BRAF-V600E degrader-1 | Compound 23 | Raf |
PROTAC BRAF-V600E degrader-1 (Compound 23) selectively induces degradation of BRAF-V600E but not wildtype BRAF. | |||
T2070 | Agerafenib | RXDX-105,CEP 32496,CEP-32496,CEP32496 | Raf , c-RET , Bcr-Abl , PDGFR , Src , c-Kit |
Agerafenib (CEP32496) is a highly potent inhibitor of BRAF. | |||
T22436 | Takeda-6d | VEGFR | |
Takeda-6d, a novel, potent DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, inhibits B-RAF and VEGFR2 with IC50 of 7.0nM and 2.2nM. | |||
T6895 | TAK-580 | MLN2480,BIIB-024 | Raf |
TAK-580 (MLN2480) is an oral, selective pan-Raf kinase inhibitor in Clinicalal trials. | |||
T6971 | Ro 5126766 | CH5126766,Avutometinib,VS-6766,RO5126766 | Raf , MEK |
RO5126766 (CH5126766) is a dual RAF/MEK inhibitor with IC50 of 8.2 nM, 19 nM, 56 nM, and 160 nM for BRAF V600E, BRAF, CRAF, and MEK1, respectively. Phase 1. | |||
T0093L | Sorafenib | Bay 43-9006 | Apoptosis , Raf , VEGFR , FLT , Ferroptosis , PDGFR , c-Kit , Autophagy |
Sorafenib (Bay 43-9006) is a multikinase inhibitor that inhibits Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/58 nM) with oral activity. Sorafenib has antitumor activity... | |||
T1792L | Regorafenib monohydrate | Raf , VEGFR , c-RET , PDGFR , c-Kit , Autophagy | |
Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine VEGFR3, PDGFR-β, KIT, RET, RAF-1, B-RAF and B-RAF(V600E) respect... | |||
T8402 | Regorafenib Hydrochloride | BAY73-4506 hydrochloride | Raf , VEGFR , c-RET , PDGFR , Autophagy |
Regorafenib Hydrochloride (BAY73-4506 hydrochloride) is a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity | |||
T2382 | Vemurafenib | RO5185426,RG7204,PLX4032 | Raf , MAPK , ACK , Src , Autophagy |
Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31/48 nM) selectively and potently. Vemurafenib exhibits antitumor activity and is used for the treatment of BRAF V600E mutation-positive... | |||
T0093 | Sorafenib tosylate | Bay 43-9006 | Apoptosis , Raf , VEGFR , FLT , Ferroptosis , PDGFR , c-Kit , Autophagy |
Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf). | |||
T6525 | GW 5074 | GW5074,Raf1 Kinase Inhibitor I | Apoptosis , Raf |
GW 5074 (Raf1 Kinase Inhibitor I)(IC50=9 nM) is an effective and specific c-Raf inhibitor. It has no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms. | |||
T8474 | Dabrafenib Mesylate | GSK 2118436B,GSK2118436 Mesylate | Raf |
Dabrafenib Mesylate (GSK2118436 Mesylate) is a B-Raf inhibitor(IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively). | |||
T1792 | Regorafenib | BAY 73-4506,Fluoro-Sorafenib | Raf , VEGFR , c-RET , PDGFR , c-Kit , Autophagy |
Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ and is orally active. Regorafenib has antitumor and anti-angiogenic activity. | |||
T38511 | AWL-II-38.3 | Ephrin Receptor | |
AWL-II-38.3 is a highly effective inhibitor of EphA3, a receptor for ephrin-A. It demonstrates potent kinase inhibitory activity against EphA3 and does not show significant cellular activity against Src-family kinases or... | |||
T68170 | Xl-281 | ||
XL-281 is a potent, selective, orally active inhibitor of wild-type and mutant RAF kinases with anti-tumor activity in multiple xenograft models; demonstrates biological activity by modulation of the RAF pathway in tumor... | |||
T71736 | AMG-628, (R)- | ||
AMG-628, (R)- is the R isomer of AMG-628 --- a potent, ATP-competitive inhibitor of Raf kinases. AMG-628 displays selectivity for Raf kinases and inhibits activation of tyrosine protein kinases such as VEGFR2, Lyn, Flt1 ... | |||
T68523 | AMG-628, (S)- | ||
AMG-628, (S)-, is the S isomer of AMG-628 --- a potent, ATP-competitive inhibitor of Raf kinases. AMG-628 displays selectivity for Raf kinases and inhibits activation of tyrosine protein kinases such as VEGFR2, Lyn, Flt1... | |||
T25350 | DPQZ | ||
DPQZ is an anti-tubulin compound acting by inducing cell apoptosis in human oral cancer cells through Ras/Raf inhibition and MAP kinases activation. | |||
T28510 | REDX05358 | REDX 05358,REDX-05358 | |
REDX05358 is a highly selective and potent pan RAF inhibitor with a potential therapeutic for BRAF and RAS mutant tumors. REDX05358 has improved therapeutic potential and predicted safety profile. REDX05358 demonstrates ... |
カタログ番号 | 製品名 | Species | Expression System |
---|---|---|---|
TMPY-05095 | RAF1 Protein, Human, Recombinant (His & GST) | Human | Baculovirus-Insect Cells |
RAF1 gene is the cellular homolog of viral raf gene (v-raf). The encoded protein is a MAP kinase kinase kinase (MAP3K), which functions downstream of the Ras family of membrane associated GTPases to which it binds direct... | |||
TMPY-04411 | YES1 Protein, Human, Recombinant (His & GST) | Human | Baculovirus-Insect Cells |
Proto-oncogene tyrosine-protein kinase Yes, also known as Proto-oncogene c-Yes, p61-Yes and YES1, is a cytoplasm protein that belongs to the protein kinase superfamily, Tyr protein kinase family and SRC subfamily. YES1 /... | |||
TMPY-03534 | CDC37 Protein, Mouse, Recombinant (His & GST) | Mouse | Baculovirus-Insect Cells |
CDC37 is a protein that is expressed in proliferative zones during embryonic development and in adult tissues, consistent with a positive role in proliferation and is required for cell division in budding yeast. CDC37 is... | |||
TMPY-01715 | CDC37 Protein, Human, Recombinant (GST) | Human | Baculovirus-Insect Cells |
CDC37 is a protein that is expressed in proliferative zones during embryonic development and in adult tissues, consistent with a positive role in proliferation and is required for cell division in budding yeast. CDC37 is... | |||
TMPY-03558 | CDC37 Protein, Mouse, Recombinant | Mouse | Baculovirus-Insect Cells |
CDC37 is a protein that is expressed in proliferative zones during embryonic development and in adult tissues, consistent with a positive role in proliferation and is required for cell division in budding yeast. CDC37 is... |
カタログ番号 | 製品名 | ||
---|---|---|---|
L1610 | FDA-Approved Kinase Inhibitor Library | 263 compounds | |
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening. | |||
L1600 | Kinase Inhibitor Library | 2700 compounds | |
A unique collection of 2700 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases; |